Tap to enable a layout that focuses on the article.
Advertisement
Business

Cardiac Science Inc.: The Irvine company said...

L.A. Times Archives

Cardiac Science Inc.: The Irvine company said Thursday that it has received approval from the Food and Drug Administration to start the second phase of human clinical trials of its non-surgical defibrillator device for high-risk heart patients. The trials are expected to begin in the next quarter at the Arizona Heart Institute in Phoenix. Phase I testing was completed at UC Irvine Medical Center, Montefiore Medical Center in New York, and the Arizona Heart Institute in Phoenix.

More to Read

Business

Inside the business of entertainment

The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.

By continuing, you agree to our Terms of Service, which include arbitration and a class action waiver. You agree that we and our third-party vendors may collect and use your information, including through cookies, pixels and similar technologies, for the purposes set forth in our Privacy Policy such as personalizing your experience and ads.

More From the Los Angeles Times

Most Read in Business

Advertisement
Advertisement